MARKET

SRPT

SRPT

Sarepta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

98.52
+4.08
+4.32%
Closed 17:35 03/30 EDT
OPEN
94.78
PREV CLOSE
94.44
HIGH
98.68
LOW
93.01
VOLUME
544.95K
TURNOVER
--
52 WEEK HIGH
158.80
52 WEEK LOW
72.05
MARKET CAP
7.66B
P/E (TTM)
-10.1884
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SRPT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SRPT stock price target is 192.70 with a high estimate of 260.00 and a low estimate of 130.00.

EPS

SRPT News

More
  • Mizuho Initiates Coverage On Sarepta Therapeutics with Buy Rating, Announces Price Target to $183
  • Benzinga · 1h ago
  • Sarepta Therapeutics (SRPT) Down 8% Since Last Earnings Report: Can It Rebound?
  • Zacks · 3d ago
  • Selloff creating bargains in healthcare - Baird
  • Seeking Alpha - Article · 5d ago
  • Edited Transcript of SRPT earnings conference call or presentation 26-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 03/24 03:12

Industry

Biotechnology & Medical Research
+4.00%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About SRPT

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
More

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.